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Background: Integrase defective lentiviral vectors (IDLV) represent a promising delivery system for immunization
purposes. Human dendritic cells (DC) are the main cell types mediating the immune response and are readily
transduced by IDLV, allowing effective triggering of in vitro expansion of antigen-specific primed CD8+ T cells.
However, IDLV expression in transduced DC is at lower levels than those of the integrase (IN) competent
counterpart, thus requiring further improvement of IDLV for future use in the clinic.
Results: In this paper we show that the addition of simian immunodeficiency (SIV)-Vpx protein in the vector
preparation greatly improves transduction of human and simian DC, but not of murine DC, thus increasing the
ability of transduced DC to act as functional antigen presenting cells, in the absence of integrated vector
sequences. Importantly, the presence of SIV-Vpx allows for using lower dose of input IDLV during in vitro
transduction, thus further improving the IDLV safety profile.
Conclusions: These results have significant implications for the development of IDLV-based vaccines.
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The improvement of delivery systems in the vaccine and
gene therapy fields is an important aspect to be consid-
ered in order to obtain an effective result. Successful use
of Integrase (IN) defective lentiviral vectors (IDLV) for
both immunization and gene therapy purposes has been
reported by several groups [1-11]. IDLV are produced by
incorporating a mutated form of the IN protein in the
recombinant lentiviral particles, thus preventing the in-
tegration of the vector genome in the target cells and
consequently improving on the safety profile of the par-
ental integration competent lentiviral vectors. IDLV take
advantage of the proficient expression of transgenes
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reproduction in any medium, provided the orare produced in the absence of integrated vector
sequences.
Non-integrated DNA forms of IDLV have been shown
to be long-lasting and transcriptionally active, both
in vitro and in vivo, as long as the transduced cells are
not dividing, even if at lower levels than those of the IN
competent counterpart [12-14]. Recent reviews have
described the progress made over the past few years and
detailed the applications of IDLV [15-19]. From the
standpoint of immunization, we demonstrated that a
single inoculum with an IDLV expressing the human im-
munodeficiency type 1 (HIV-1) envelope protein in the
mouse immunogenicity model was able to elicit strong
and long lasting specific immune responses in the ab-
sence of vector integration, thus providing a safe and ef-
ficient delivery for vaccine purposes [9-11]. Importantly,
several groups confirmed the use of IDLV as an effective
vaccine delivery strategy [5-7], and we provided evidence
that simian immunodeficiency (SIV)-based IDLV can betd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Viral particles were produced by transient transfection
of 293 T cells with (right) or without (left) plasmid expressing
flagged SIV-Vpx. Supernatants were harvested after 48 hrs and viral
particles were purified onto a double-step sucrose gradient prior to
WB analysis with the indicated antibodies. The positions of
migration of molecular mass markers (in kilodaltons) are indicated
on the right.
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cerning the potential use in a human setting, we recently
demonstrated that IDLV-transduced human antigen pre-
senting cells, such as monocyte-derived dendritic cells (DC)
and macrophages, were able to induce antigen-specific T
cells expansion of primed T cells in vitro using Influenza
Matrix 1 protein (Flu-M1) as a model antigen [20].
Despite its potential, a limitation in the use of IDLV
for a preventive vaccine is represented by the lower ex-
pression of the transgene compared to the IN competent
counterpart. Indeed, although many vaccination strat-
egies in small animals are successful, they may be less ef-
fective in larger animals, such as non-human primates
or humans. In this setting, improving on the amount of
the antigen delivered by IDLV is a critical issue, espe-
cially in the antigen presenting cells that play an essen-
tial role in the induction and expansion of vaccine-
specific immune response. In this regard, Berger and
colleagues demonstrated that SIV virus like particles
(VLP) containing the SIVMAC251-Vpx protein greatly
increased the transduction efficiency of IDLV in human
DC and macrophages [21]. These results are in line with
work from other groups, showing that Vpx of the
SIVSM/HIV-2 lineage acts on cytoplasmic SAMHD1 pro-
tein, a HIV-1 restriction factor expressed in cells of the
myeloid lineage that inhibits an early step of the viral life
cycle, and demonstrating that SIV-Vpx induces protea-
somal degradation of SAMHD1, ultimately enhancing
HIV-1 infection in myeloid-lineage cells [22,23].
To exploit the use of SIV-Vpx in the context of IDLV-
based vaccines, we evaluated whether IDLV containing
SIV-Vpx (IDLV/Vpx) was more efficient than IDLV with-
out Vpx in enabling functional expansion of primed
antigen-specific CD8+ T cells. Results indicated that
IDLV/Vpx expressing Flu-M1 was superior to IDLV alone
in inducing in vitro expansion of primed Flu-M1-specific
CD8+ T cells from PBMCs of Flu-M1 positive healthy
donors, in the absence of integration. In addition, we show
that SIV-Vpx did not improve the transduction efficiency
of murine BM-derived DC, while significantly increased
the transduction of simian DC, suggesting that the mouse
model may not be appropriate to test an IDLV/Vpx based
vaccine. We confirmed this hypothesis by immunizing
mice with IDLV or IDLV/Vpx expressing HIV-Env and
comparing at different time points the levels of immune
responses induced.
Results
SIV-Vpx increases the transduction efficiency of IDLV in
human DC
Presence of SIV-Vpx in viral particles was confirmed by
Western blot analysis as described in Figure 1 and in the
Methods section. Effect of SIV-Vpx on transduction effi-
ciency of IDLV on human DC was evaluated on eightdifferent donors using normalized amounts (MOI 1) of
IDLV-GFP, IDLV-GFP/Vpx or IN competent lentiviral
vector (LV-GFP) expressing GFP (Figure 2). GFP expres-
sion in transduced DC was evaluated in terms of per-
centage of GFP positive cells and mean of fluorescence
intensity (MFI). At day 5 from infection, an average of
1.0% of GFP+DC was detected after infection with IDLV-
GFP, while 26.5% and 18.9% of DC expressed GFP after
transduction with the same amount of IDLV-GFP/Vpx or
integrating LV-GFP, respectively (Figure 2a). These data
indicated that inclusion of SIV-Vpx during vector prepar-
ation induced a statistically significant increment in the ef-
ficiency of transduction (IDLV/Vpx vs IDLV, P < 0.05),
confirming data already shown by other groups using
SIV-Vpx VLP [21]. As expected, MFI in DC transduced
with the integrating LV-GFP was higher than MFI in DC
transduced with IDLV-GFP or IDLV-GFP/Vpx (179 MFI
vs 53 MFI and 100 MFI, respectively) (Figure 2b).
SIV-Vpx improves the ability of IDLV-transduced human
DC to induce expansion of M1-specific CD8+ T cells
In order to evaluate if inclusion of SIV-Vpx in the vector
preparation could influence the functionality of human
DC, their ability to expand antigen specific CD8+ T cells
after IDLV transduction was analyzed. For this we used
Figure 2 Transduction of human DC with lentiviral vectors expressing GFP. Human DC from different donors were transduced with IDLV-
GFP, IDLV-GFP/Vpx or integrating LV-GFP (MOI 1). After 5 days from transduction the percentage of GFP-expressing DC (a) and the mean of
fluorescence intensities (MFI) of GFP + cells (b) were measured. Results are expressed as average from eight different experiments. Error bars
represent SD.
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four selected Flu-M1 positive donors were used showing
a percentage of M1-pentamer positivity within gated per-
ipheral CD8+ T lymphocytes ranging from 0.15% to
0.34% (data not shown). These numbers represent base-
line values of M1-reactive CD8+ T cells present in
healthy donors that previously encountered influenza
virus. DC from Flu-M1 positive donors were transduced
with equal amount of vectors expressing influenza M1
protein, including IDLV-M1, IDLV-M1/Vpx, or integrat-
ing LV-M1. Vectors were constructed as already
described [20] and used as indicated in Materials and
Methods. DC transduced with vectors expressing M1 or
control vector expressing GFP (IDLV-GFP/Vpx) were co-
cultured with CD14-depleted autologous PBMC for
10 days. As controls, mature DC pulsed with M1-specific
peptide (GIL) or left untreated were co-cultured with au-
tologous cells, as above. The presence and expansion of
M1-specific CD8+ T cells was evaluated by pentamer
staining, and the functional activity of these cells was ana-
lyzed by IFN-γ production in the ELISPOTassay.
In a representative experiment shown in Figure 3a, DC
transduced with low levels of any M1-vector were able to
expand M1-specific T cells. In particular, Figure 3b shows
that while DC transduced with IDLV-M1 were able to in-
duce a detectable expansion of M1-specific CD8+ T cells,
DC transduced with IDLV-M1/Vpx induced higher sig-
nificant expansion of M1-pentamer positive cells (2.1%
and 19.7%, respectively; P < 0.05). Importantly, DC trans-
duced with IDLV-M1/Vpx were able to induce an expan-
sion of antigen specific CD8+ T cells similar to that
observed in the co-culture with integrating LV-M1-
transduced DC (18.6%; P < 0.05 compared to IDLV-M1
and IDLV-M1/Vpx). Untreated DC, as well as DC infected
with control IDLV expressing GFP as an unrelated anti-
gen, did not induce significant expansion of M1-specific
CD8+ T cells. DC pulsed with intra-assay positive control
GIL peptide showed the highest expansion of antigen-
specific T cells (32.2%).Antigen-specific CD8+ T cells expanded by
IDLV-M1/Vpx-transduced DC are functional
Functional analysis of M1-specific CD8+ T cells was per-
formed by IFN-γ ELISPOT (Figure 3c). The expanded
CD8+ T cells derived from the stimulation of CD14-
depleted PBMC with IDLV-M1 transduced DC were able
to produce IFN-γ in the presence of GIL peptide (aver-
age of 1086 SFC/106 cells). As expected, the number of
IFN-γ producing cells was higher in lymphocytes stimu-
lated by DC transduced with IN competent LV-M1
(5500 SFC/106 cells; P < 0.05). Of note, IDLV-M1/Vpx
transduced DC induced functional CD8+ T cells show-
ing a strong improvement in the number of SFC (6500
SFC/106 cells) which was significantly higher than IDLV-
M1 (P < 0.05) and similar to that observed when using
IN competent LV-M1 (P > 0.05). The positive control
represented by DC pulsed with M1-specific peptide
showed similar results (7100 SFC/106 cells). No signifi-
cant IFN-γ production was detected in the case of co-
culture with DC infected with IDLV-GFP or untreated
DC (Figure 3c).
Overall these results indicate that IDLV-M1/Vpx-
transduced DC efficiently enabled in vitro expansion of
functional primed antigen specific CD8+ T cells. In par-
ticular, the increase in transduction efficiency in the
presence of SIV-Vpx determined a strong and significant
expansion of functional antigen-specific CD8+ T cells.
Transduction with IDLV-M1/Vpx does not induce increase
in DNA integration
To evaluate if the increased transduction efficiency of
DC with IDLV-M1/Vpx was due to increased vector in-
tegration, DNA recovered from DC transduced with
IDLV-M1, IDLV-M1/Vpx and LV-M1 were used in a
vector-specific Alu-PCR for the analysis of integrated
vector sequences, as described in Materials and Meth-
ods. Only DC transduced with IN competent LV-M1
showed clear evidence of integrated vector sequences in
as low as 0.1 ng of genomic DNA, while there was no
Figure 3 Evaluation of M1-specific CD8+ T cell expansion by using transduced DC as antigen presenting cells. DC were transduced with
IDLV-M1, IDLV-M1/Vpx, integrating LV-M1 or IDLV-GFP/Vpx as an unrelated antigen (MOI 1). M1-specific peptide-pulsed (GIL-pulsed) or unpulsed
DC (NT) were used as positive and negative controls, respectively. For pentamer assay (a and b), cells were stained with anti-CD8 PE-Cy5
antibody and PE-labeled HLA-A*0201 pentamer presenting the influenza matrix M1 epitope. The percentage of pentamer + cells was calculated
within CD8+ T cells and in (a) a representative experiment is shown. (b) Percentages of CD8+ pentamer + T cells evaluated in four different
healthy donors are indicated. Graphs show means ± SD. (c) The functionality of expanded CD8+ T cells was evaluated by IFN-γ-ELISPOT in the
presence of M1 specific peptide. Results are expressed as spot forming cells (SFC) per 1x106 cells.
Figure 4 Lentiviral vector sequences in human DC transduced
with IDLV-M1, IDLV-M1/Vpx and LV-M1. At day 7 from
transduction DNA was extracted and used in semi-quantitative Alu-
PCR for evaluating integrated vector sequences (left panels, a
representative experiment out of three performed is shown). The
293 cell line stably transduced with the TY2-GFP-IRES-Neo vector
(293/LV-GFP-Neo) was used as standard for evaluating integrated
vector copies. PCR samples were run on a Ethidium bromide stained
2% agarose gel. Real-time DNA PCR was used for evaluating 2-LTR
and late reverse transcription products copy number (right panel,
average values of three independent experiments are shown), as
described in Materials and Methods.
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transduced DC in as high as 10 ng of genomic DNA
(Figure 4, left panels). The 293 cell line stably transduced
with a lentiviral vector expressing the Neomycin resist-
ance gene (293/LV-Neo) was used as standard for evaluat-
ing presence of integrated vector sequences. Conversely,
higher levels of late reverse transcription products and cir-
cular 2-LTR forms were found in DC transduced with
IDLV-M1/Vpx than in DC transduced with IDLV-M1 or
LV-M1 (Figure 4, right panel).
To further evaluate the effect of SIV-Vpx on the re-
sidual integration activity of IDLV, vectors expressing
the neomycin resistance gene were generated with or
without Vpx (IDLV-Neo/Vpx and IDLV-Neo, respect-
ively) and used to transduce human 293 cells. IN compe-
tent LV-Neo was used as a reference positive control.
Cells were infected with serial dilutions of each vector
and subjected to selection with Geneticin, as described
[9,10]. Results from two independent experiments showed
that the number of colonies in the IDLV-Neo/Vpx-
transduced Geneticin-selected cells was similar to that
found in the IDLV-Neo-transduced Geneticin-selected
cells (Table 1), indicating that SIV-Vpx did not alter the
residual integration activity of IDLV. As expected, the
number of colonies in the IN competent LV-Neo
Table 1 DNA recombination frequencies of IN defective vectors with and without Vpx and of IN competent control
vector on 293 cell line
Vector Experiments Number of colonies for 1x106 RT counts Ratio
Defective/competent
IDLV-Neo Exp1 129 6,6x10-4
Exp2 99 6,3x10-4
IDLV-Neo/Vpx Exp1 116 5,95x10-4
Exp2 108 6,9x10-4
LV-Neo Exp1 1,95x105 -
Exp2 1,56x105 -
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the indicated doses, IDLV-Neo and IDLV-Neo/Vpx
integrated between 5.95 × 10−4 and 6.9 × 10−4 times less
frequently than the IN competent vector, consistently
with what has been found in other systems [9,10], dem-
onstrating that IDLV maintained the integration defi-
cient phenotype, regardless the presence of SIV-Vpx,
with negligible amounts of residual integration activity.Figure 5 Transduction of murine DC with lentiviral vectors expressing
differentiated with GM-CSF (GM-DC) were transduced with normalized amo
(no vector). After 5 days from transduction cells were analysed by FACS to
experiment out of three performed is shown. The percentages of GFP-expres
differentiated in the presence of GM-CSF alone (GM-DC), GM-CSF and IL-4 (GM
amounts of IDLV-GFP, IDLVV-GFP/Vpx (MOI 4) or left untreated (no vector). Th
GFP expressing cells are indicated within the histograms. A representative expSpecies-dependent susceptibility to IDLV/Vpx
The efficiency of IDLV in inducing a broad and long
lasting immune response in murine models has been
already established [18,19]. In order to evaluate if the
mouse model of immunization could represent a suit-
able model for studying the in vivo effectiveness of a
IDLV/Vpx based vaccine, bone marrow (BM)-derived
DC from naïve Balb/c mice were transduced with IDLV-GFP. (a) Murine bone marrow-derived dendritic cells (BMDC)
unts of IDLV-GFP, IDLV-GFP/Vpx or LV-GFP (MOI 1) or left untreated
evaluate the percentage of GFP expressing cells. A representative
sing CD11c+DC are indicated within the dot plots. (b) Murine BMDC
+IL4-DC) or Flt3L alone (FL-DC) were transduced with normalized
e expression of GFP was analyzed on CD11c+population. Percentages of
eriment out of three performed is shown.
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As shown by a representative experiment depicted in
Figure 5a, the percentage of GFP+DC was similar,
around 4%, in both IDLV and IDLV/Vpx transduced
CD11+ DC. These results suggest that the presence of
SIV-Vpx in the IDLV preparation did not improve mur-
ine DC transduction and that the efficacy of a vaccine
based on IDLV/Vpx should not be tested in mice. It has
been shown that BM-derived cells differentiated in vitro
by using different cytokines and conditions generate DC
with different morphology and characteristics [24]. To
confirm the data obtained using GM-CSF differentiated
DC (GM-DC), BM-derived cells were differentiated also
with GM-CSF and IL-4 (GM+ IL4-DC) or fms like tyro-
sine kinase 3 ligand (Flt3L) (FL-DC) cytokines. All these
DC were transduced with IDLV-GFP or IDLV-GFP/Vpx
at 4 MOI and the GFP expression analyzed after 5 days.
A higher MOI was selected in order to verify if SIV/Vpx
could be more active in a less sensitive model, such as
murine cells. As shown in Figure 5b, SIV-Vpx did not
generate any improvement in the transduction efficiency
of IDLV. We also analyzed the MFI on GFP+murine
DC from different experiments and results indicated that
IDLV-GFP/Vpx transduced DC did not show signifi-
cantly higher MFI than IDLV-GFP transduced ones (dataFigure 6 Immune response in immunized mice. (a) HIV-1-JR-FL envelope
blood cells from mice immunized with IDLV-JR (black bars), IDLV-JR/Vpx (g
Analysis was performed on blood cells stimulated overnight with H2-Dd re
Methods section. IFN-γ producing T cells are expressed as SFC/106 cells aft
deviation among mice of the same group, and P-values are indicated for in
ELISA in plasma samples of mice immunized with IDLV-JR (black bars) or ID
from immunized mice were analyzed separately. Results are expressed as t
deviations amongst mice of the same group. P-values are indicated for intenot shown). We seldom found a minor population of
transduced cells with higher MFI (less than 2%), regard-
less of the presence of Vpx or of the DC-differentiating
cytokines. This is likely due to experimental variability
when using primary cells treated with different stimuli.
Despite these data, an in vivo immunization in mice
was performed. HIV-gp120 was used as an antigen in
order to evaluate both cellular and humoral antigen-
specific immune response after a single immunization
[9]. As shown in Figure 6a, the induction of gp120 specific
CD8+ T cells was similar in mice immunized with IDLV-
JR or IDLV-JR/Vpx at both 6 weeks after immunization
(437 and 546 SFC/106, respectively; P > 0.05) and later on
at 9 weeks after injection (289 and 537 SFC/106, respect-
ively; P > 0.05). The presence of anti-gp120 antibodies was
evaluated at 6 weeks after immunization in plasma of
immunized mice by ELISA (Figure 6b). As expected, the
immunization with IDLV did not induce high level of anti-
bodies as already observed in other studies [9,25]. Of note
the immunization with IDLV-JR/Vpx did not improve
humoral response. To verify that the mice in both groups
had been injected with the same amount of IDLV vectors,
anti-HIV Gag antibody response was evaluated. Indeed,
the injection of lentiviral vectors induces antibodies direc-
ted versus the gag protein present in the viral particlesT-cell responses measured by the IFN-γ ELISPOT assay on peripheral
rey bars) and naïve mice (empty bars) at 6 and 9 weeks from injection.
stricted specific Envelope JR-9mer peptide, as described in the
er background subtraction. The error bars indicate the standard
tergroup comparisons. (b) Anti-gp120 and anti-p24 IgG measured by
LV-JR/Vpx (grey bars) at 6 weeks after immunization. Plasma samples
he IgG mean titer of 4 mice per group. Error bars indicate the standard
rgroup comparisons.
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were similar in plasma from both groups of mice, con-
firming that the two groups received similar amounts of
vectors. All together these results suggest that the mouse
model is not suitable for the validation of IDLV/Vpx
-based vaccine.
Non-human primates (NHP) represent an important
model for evaluating vaccine approaches against many
infectious diseases such as HIV-1, malaria and tubercu-
losis. To evaluate if the use of IDLV/Vpx might be ad-
vantageous in NHP, simian DC derived from 4 rhesus
and 4 cynomolgus monkeys were transduced with GFP-
expressing IDLV with or without SIV-Vpx. As controls,
we used SIV-based IDLV and LV expressing GFP. This
was done in order to evaluate differences in transduction
ability among the HIV- and SIV-based vectors in simian
cells. As shown in Figure 7, IDLV-GFP/Vpx showed a
significant increase in the percentage of transduced DC,
compared to IDLV-GFP (9.3% vs 2.5%; P < 0.05). The in-
tegrating LV counterpart showed higher percentage than
that observed in both IDLV (21.7%; P < 0.05 compared to
both IDLV-GFP and IDLV-GFP/Vpx). Compared to
human DC, simian DC were less susceptible to IDLV-
GFP/Vpx transduction. This is likely due to the presence
of species-specific restriction factors, as it has been pre-
viously shown using HIV-1 in simian cells [27,28]. As
expected, SIV-based IDLV and LV were more efficient in
transducing simian DC than the corresponding HIV-
based vectors (Figure 7, left panel) at the same low MOI
(46% and 84%, for the SIV-based IN defective and IN
competent vectors, respectively). These results suggest
that SIV-based IDLV, compared to HIV-based IDLV/Vpx,
represent a better vector for testing the efficacy of IDLV-
based vaccine in a relevant NHP animal model.
Discussion
In the present study we demonstrate that IDLV/Vpx effi-
ciently transduce human monocyte-derived DC, leadingFigure 7 Transduction of simian DC with lentiviral vectors expressing
transduced with equal amounts (MOI 1) of HIV-based IDLV-GFP, IDLV-GFP/V
panel). After 5 days from transduction cells were analysed by FACS to evalu
average from eight different experiments. Error bars represent SD.to an improvement of the functional properties of IDLV,
as evaluated by in vitro expansion of antigen-specific
CD8+ T cells. This is important since DC represent a
major cell type mediating the immune response and re-
cent work has shown that vaccines delivered by IDLV tar-
geting DC induce strong antigen-specific immunity [7]. A
recent report showed that non-infectious SIVMAC251 VLP
carrying Vpx efficiently improved transduction of human
antigen presenting cells with IDLV [21]. To evaluate a fu-
ture use of this vector for vaccine purposes, the functional
ability of DC to expand an antigen-specific response after
transduction with IDLV/Vpx was analyzed. We opted for
a lower input virus than previously reported [20] in order
to further increase the safety level of the vaccine and to
better discriminate between IDLV and IDLV/Vpx func-
tional ability. The transduction efficiency of IDLV/Vpx
was compared with IDLV alone or with integrating LV,
and we showed that IDLV/Vpx was significantly more effi-
cient than IDLV alone and similar to integrating LV. Our
results are consistent with those published by Berger et al.
and could be explained by recent papers showing that
SIV-Vpx interacts with SAMHD1, a HIV-1 restriction fac-
tor in myeloid cells, such as DC and macrophages, that
inhibits an early step of the viral life cycle [21,22]. It has
been demonstrated that SIV-Vpx relieves the inhibition of
lentivirus infection leading to highly efficient proteasome-
dependent degradation of the protein SAMHD1 [23].
Consequently, through the action of Vpx, IDLV becomes
“fully competent” reaching high levels of transduction,
with expression levels approaching those observed with
integrating LV.
We also demonstrated that the percentage of func-
tional antigen-specific CD8+ T cells recovered after co-
culture with IDLV/Vpx transduced DC was significantly
higher than that observed in Vpx-less IDLV-transduced
DC co-cultures, and similar to that of integrating LV-
transduced DC. To ascertain that the increased expres-
sion in IDLV/Vpx-transduced DC was not caused by anGFP. Simian monocyte-derived DC from different monkeys were
px, LV-GFP (left panel) or with SIV-based IDLV-GFP or LV-GFP (right
ate the percentage of GFP expressing cells. Results are expressed as
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analyses on transduced DC were performed. Our results
demonstrated that only the late reverse transcription
products and the 2-LTR circular forms were increased in
the IDLV/Vpx transduced DC, in the absence of detect-
able integrated vector sequences. This suggests that the
higher transduction efficiency of IDLV/Vpx is due to a
more efficient reverse transcription culminating with a
higher number of transcriptionally active episomal forms
of vector DNA in the absence of integration, as previ-
ously reported in similar systems [21]. Importantly, re-
cent reports [29,30] have shown that SAMHD1 in
dendritic cells is a deoxynucleoside triphosphate tripho-
sphohydrolase which restricts the replication of HIV-1
by depleting the intracellular pool of dNTP. This would
decrease HIV-1 DNA synthesis rate ultimately slowing
reverse transcription and impairing viral replication.
While it is likely that the effect of Vpx is not specifically
on reverse transcription, the Vpx-induced degradation of
SAMHD1 results in a larger intracellular dNTP pool
which allows reverse transcription to proceed and
restores permissiveness of the cells to infection.
The efficacy of IDLV as a delivery system for
immunization purposes in vivo has been demonstrated
in mice by our group and other groups in different
model systems [18,19]. It is now firmly established that
in mice IDLV-vectored antigens are able to induce sus-
tained immune response over time, which is protective
against challenge with wild-type virus and tumor cell
lines expressing the model antigen. To verify the ability
of SIV-Vpx to increase the transduction efficiency of im-
mune cells and consequently to induce an improved im-
mune response in the mouse model, we firstly evaluated
the transduction efficiency of GFP-expressing IDLV/Vpx
on murine BM-derived DC, in comparison with that of
IDLV alone. Our results indicated that SIV-Vpx did not
improve on the transduction efficiency of murine DC
differentiated either with GM-CSF alone or GM-CSF
and IL4 or Flt3L, suggesting that mice do not represent
a proper model to evaluate an IDLV/Vpx-based vaccine
strategy. To further verify the suitability of the mouse
model, we immunized mice with IDLV or IDLV/Vpx
and the data confirmed the results obtained in vitro.
One explanation could be that the murine analogue of
SAMHD1, the mouse IFN-γ induced gene (MG11)
which presents only 72% identity with SAMHD1 [31], is
not properly targeted by SIV-Vpx. Indeed, a recent re-
port [30] showed that while Vpx counteracted human
and rhesus SAMHD1, it was not active against the
mouse homolog of SAMHD1. In particular, Vpx pre-
vented the SAMHD1-mediated decrease in dNTP con-
centration by inducing degradation of human and rhesus
macaque SAMHD1, but had no effect on mouse
SAMHD1.Conversely, based on SIV-Vpx origin, the most appro-
priate animal model to test IDLV/Vpx vaccine should be
the NHP. Our data showed that IDLV/Vpx was signifi-
cantly more efficient in transducing simian DC com-
pared to IDLV alone, but less efficient than integrating
LV. The different susceptibility of simian DC compared
with human DC to HIV-1 infection has been already
established [27,28,32,33]. Bypassing the restriction factor
counteracted by Vpx could not be sufficient for HIV-
based IDLV to become fully competent in simian DC.
Other species specific restrictions could still interfere
with the transduction efficiency, and this effect could be
particularly evident at low viral input [27,28,32,33]. To
overcome these issues and to set the optimal conditions
for inducing a proficient immunization with an IDLV-
based vaccine in vivo, two avenues might be taken under
consideration. The first one aims at using SIV-based
IDLV, in place of HIV-based IDLV, in monkeys, since
SIV-based vectors not only intrinsically contain Vpx in
the packaging vector, but also the full complement of
viral proteins necessary for counteracting the specie-
specific restriction factors present in simian DC
[27,28,32,33]. Indeed, we show here that the efficiency of
transduction of simian DC with SIV-IDLV was compar-
able to that observed in human DC transduced with
IDLV/Vpx and higher than that observed with HIV-
based IDLV and integrating LV in simian DC. We may
thus speculate that immunization with a SIV-based
IDLV in monkeys could mimic a vaccine delivered by
HIV-based IDLV/Vpx in humans. The second option
might consider the use of HIV-based IDLV/Vpx in a
humanized mouse model, such as the humanized Bone
marrow/Liver/Thymus (BLT) mice [34]. Humanized BLT
mice have been shown to exhibit a complete, systemic and
self-renewing reconstitution of the human hematopoietic
lineages including T, B, monocyte, DC and natural killer
cells, thus facilitating the induction and evaluation of func-
tional human immune responses following immunization.
In addition it has been reported that BLT mice have muco-
sal reconstitution with human immune cells which is com-
petent for mucosal or systemic infection with replication
competent HIV-1 virus [35], necessary for evaluating the
outcome of a successful immunization. Recently, it has
been proven that this model perfectly mimics human re-
sponse to topical application of the tenofovir to prevent
HIV-infection, as already seen in the human clinical trial
CAPRISA 004 [36], further validating BLT mice as a good
model in the HIV-preventive treatments [37]. To date, vac-
cine studies in BLT mice have not yet been performed, but
this model seems to be eligible also for studying induction
of immune responses by vaccine strategies. In conclusion,
our data strongly suggest that IDLV/Vpx represent a new,
efficient and safe delivery system useful for vaccine strat-
egies, to be tested in vivo in a proper animal model system.
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These results indicate that inclusion of SIV-Vpx protein
in IDLV preparations significantly improves the trans-
duction of DC, thus increasing the ability of transduced
DC to act as functional antigen presenting cells. Further,
the presence of SIV-Vpx allows for using a lower
amount of input IDLV during in vitro transduction, thus
improving the safety profile of IDLV and the potency of
the immune response with significant implications for
the development of vaccines based on IDLV.
Methods
Vector construction
Transfer vectors expressing Flu-M1 (pTY2CMV-M1W)
and GFP (pTY2CMV-GFPW) have been already described
[20]. Transfer vector pTY2CMV-JRW, expressing the HIV-
1JR-FL envelope, was obtained by removal of the mGM-CSF
cassette from plasmid pTY2CMV-JRmZ [9]. Transfer vec-
tor pTY2-GFP-IRES-Neo, which contains the Neomycin
phosphotransferase resistance gene (Neo), was obtained by
cloning a ClaI/SalI restricted fragment of DNA from
pTY2CMV-GFP, containing the CMV promoter and the
GFP sequence, and a SalI/EcoRV restricted fragment of
DNA from plasmid pFB-Neo (Stratagene, Agilent Tech-
nologies, Inc., Santa Clara, CA), and containing the IRES2-
Neo sequence, into the pTY2 ClaI/EcoRV backbone plas-
mid. The HIV-based packaging plasmids IN competent
(pCMVdR8.2) and IN defective (pcHelp/IN-), the SIV-
based packaging plasmids IN competent (pADSIV3+) and
IN defective (pADSIVD64V), and the VSV.G envelope-
expressing pMD.G plasmids have been already described
[9,10,38]. For construction of SIV-Vpx expressing plasmid,
Vpx derived from the SIVMAC251 strain was modified by
fusing it to a heterologous membrane targeting domain
derived from c-Src and to a FLAG epitope, into the plasmid
pEF/myc/cyto (Gibco Invitrogen, Carlsbad, CA). This
modification allows high levels of incorporation of SIV-Vpx
into HIV-1 virus particles (VLP) and will be presented in
more details elsewhere (Cimarelli et al., manuscript submit-
ted). Expression of SIV-Vpx and incorporation into HIV-1
VLP was verified by Western blot using a polyclonal anti-
FLAG antibody (Sigma-Aldrich Chimie S.a.r.l., Lyon, France)
while presence of Gag was evaluated with an anti-Gag
polyclonal antibody (NIH Repository Reagents, Cat. #4250),
as primary antibodies. Secondary antibodies included an
anti-rabbit HRP-conjugated IgG (Dako, Dako France S.
A.S.). The immunocomplexes were visualized using
chemiluminescence ECL detection system (Super Signal
West Dura Extended Duration Substrate- PIERCE/
Thermo Scientific, USA).
Production of recombinant vectors
The human epithelium kidney 293 T cell line was main-
tained in Dulbecco's Modified Eagle’s medium (Euroclone,Life Sciences Division, Pero, Milan, Italy) supplemented
with 10% fetal bovine serum (FBS) (Euroclone) and 100
units/ml of penicillin-streptomicin-glutamine (PSG) (Gibco
Invitrogen, Paisley, UK). For production of recombinant
lentiviral vectors IN defective (IDLV) and IN competent
(LV) expressing GFP (IDLV-GFP, IDLV-GFP/Vpx and
LV/GFP), M1 (IDLV-M1, IDLV-M1/Vpx and LV/M1),
HIV-1 gp120JR-FL (IDLV-JR and IDLV-JR/Vpx) or Neo-
mycin resistance gene (IDLV-Neo, IDLV-Neo/Vpx and
LV-Neo), 293 T cells were transiently transfected on
10 cm Petri dishes using the Calcium Phosphate-based
Profection Mammalian Transfection System (Promega
Corporation, Madison WI, USA) as previously described
[9,10]. A total of 12 μg of plasmid DNA were used for
each plate in a ratio 6:4:2 (transfer vector: packaging vec-
tor: VSV.G vector). For the preparation of IDLV contain-
ing SIV-Vpx and expressing GFP or Flu-M1 (IDLV-GFP/
Vpx and IDLV-M1/Vpx, respectively), 10 μg of SIV-Vpx
codifying plasmid were included in the transfection. Re-
combinant IDLV and LV were produced using pcHelp/IN-
and pCMVdR8.2 packaging plasmids, respectively, if HIV-
based, or pADSIVD64V and pADSIV3+, if SIV-based.
After 48 h, cell culture supernatants were recovered,
cleared from cellular debris and passed through a 0.45 μM
pore size filter (Millipore Corporation, Billerica, MA,
USA). Concentration vectors containing supernatants
were ultracentrifuged (Beckman Coulter, Inc., Fullerton,
CA, USA) on a 20% sucrose gradient (Sigma Chemical
Co. St. Louis, MO, USA) and viral pellets were resus-
pended in 1X PBS. Viral titers for the GFP-coding vectors
were normalised by exogenous reverse transcriptase (RT)
activity assay [39] and titration on 293 T cells [9,40]. For
the Flu-M1 and the HIV-1JR-FL Envelope-coding IDLV and
LV, titration was performed by the RT activity assay over
standards of known infectivity and the vector-associated
RT activity was compared with the one of IDLV-GFP or
LV-GFP-coding virions of known infectious titers, thus
allowing for the determination of their infectious titer
units [40].
Generation of primary human and simian monocyte-
derived DC and transduction with lentiviral vectors
Human cells were obtained from healthy blood donor
volunteers. Healthy Macaca mulatta (rhesus monkey) and
Macaca fascicularis (cynomolgous monkey) were housed
in the non-human primate facility at the Ente Nazionale
Energia Alternativa (ENEA) in Casaccia (Rome, Italy). The
animals were kept according to international, European
and Italian guidelines.
Human and simian peripheral blood mononuclear
cells (PBMC) were isolated by density gradient centrifu-
gation using Lympholyte (Cedarlane Laboratories Ltd.,
Burlington, NC, USA). PBMC were incubated with anti-
human CD14 microbeads (Miltenyi Biotec, Calderara di
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tions. Purified monocytes were resuspended in medium
RPMI 1640, containing 10% FBS (Euroclone), 100 units/ml
of PSG (Gibco Invitrogen), non-essential amino acids
(Gibco Invitrogen), sodium pyruvate 1 mM (Euroclone)
and HEPES buffer solution 25 mM (Euroclone). Mono-
cytes were seeded in 24 well plate at 1x106 per well in 1 ml
in the presence of 50 ng/ml GM-CSF (Immunological
Sciences, Rome, Italy) and 35 ng/ml of IL-4 (Immuno-
logical Sciences) to differentiate monocytes in DC. On day
5, 0.25x106 DC were infected with 1 multiplicity of infec-
tion (MOI) of viral supernatant. The cells were centrifuged
for 1 hour at 1500 rpm. After 2 hrs of incubation at 37°C,
cells were washed once and seeded in complete medium
supplied with cytokines. After 5 days from transduction
with lentiviral vectors expressing GFP, the expression of
GFP was analysed by FACScalibur (BD Biosciences, San
Jose, CA, USA).
Generation of murine bone marrow-derived DC and
transduction with lentiviral vectors
Bone marrow (BM) was recovered from Balb/c mice, as
described [41]. Briefly, BM cells were obtained from
tibiae by syringe insertion into one end of the bone and
flushing with RPMI medium. For DC generation, cells
from BM were suspended at 1x106 cells/ml in complete
medium containing 50 μM 2- mercaptoethanol (Sigma
Chemicals, Co., St. Louis, MO, USA) and 10 ng/mL of
rmGM-CSF (Peprotech, Rocky Hill, NJ, USA), 10 ng/ml
recombinant mouse GM-CSF and 20 ng/ml IL-4 (Pepro-
tech) or 40 ng/ml recombinant mouse Flt3L (R&D Sys-
tems, Inc., Minneapolis, MN, USA), to differentiate GM-
DC, GM+ IL4-DC or FL-DC, respectively. GM-CSF and
IL-4 were added in fresh medium each 3 days. At 7 days,
loosely adherent cells were then collected, analyzed for
CD11c expression and transduced with lentiviral vectors
expressing GFP, as above described. After 5 days, BMDC
were surface stained for CD11c FITC (BD Biosciences)
and analyzed by FACScalibur for the expression of GFP.
In vitro expansion of human antigen-specific CD8+ T cells
Human donors were selected based on the presence of
CD8+ T cells specific for the HLA-A*0201-restricted M1
epitope (GILGFVFTL), as described [20]. PE-labeled
HLA-A*0201 pentamer presenting the influenza matrix
M1 epitope (aa 58–66) (M1-pentamer) and control PE-
labeled HLA-A*0201 pentamer presenting the HIV-gag
peptide (SLY-pentamer) were provided by Proimmune
(The Magdalen Centre, Oxford Science, Oxford, U.K.).
PBMC (2x106) were washed in wash buffer (0.1% BSA in
PBS), spun down and resuspended in residual liquid. Ei-
ther M1- or SLY-pentamer (2 μl) was added to the cells,
incubated at 4°C for 20 minutes and further incubated for
15 min on ice with PE-Cy5-labeled anti-CD8 monoclonalantibody (Immunological Sciences). After washing, cells
were resuspended in 1% formaldehyde in PBS and CD8
+/pentamer+ cells were analyzed on FACSCalibur (BD
Biosciences) using CellQuest software. Monocytes from
M1-positive selected donors were isolated, differentiated
into DC and transduced with lentiviral vectors expressing
M1, as above described. Maturation of DC was induced
by adding lipopolysaccharide (LPS, 0.5 μg/ml; Sigma-
Aldrich) to the medium on day 7, and on day 8 mature
DC were used for stimulation of autologous PBMC. In
particular, DCs transduced with lentiviral vectors expres-
sing M1 protein, GFP or left untreated were co-cultured
with autologous PBMC depleted of CD14 cells, at an ef-
fector (T cell)-to-stimulator (APC) ratio of 10:1 for 10 days
in the presence of IL-2 (50U/ml; BD Biosciences) and IL-7
(5 ng/ml; Thermo Scientific, Rockford, IL).Analysis of M1-specific CD8+ T cells by pentamer staining
and IFN-γ ELISPOT
The expansion of M1-specific CD8+ T cells was evalu-
ated by using PE-labeled M1-pentamer, as described
above. The IFN-γ ELISPOT assay was performed by using
reagents from BD Biosciences. The 9mer containing the
HLA-A*0201 restricted M1 epitope (GILGFVFTL) (Primm
s.r.l. San Raffaele Biomedical Science Park, Milan, Italy) and
the HLA-A*0201 restricted HIV-1 gag 9mer peptide
(SLYNTVATL) (Primm s.r.l.) were used at 1 μg/ml as spe-
cific and unrelated stimuli, respectively. Medium alone and
PHA (Sigma, Chemical Co. St. Louis, MO, USA) were used
as negative and positive controls, respectively. Samples were
scored positive when was present a minimum of 50 spots
per 106 cells and a fold of 2 or higher compared to the un-
related peptide.Residual integration activity of the IN defective vector
The human epithelium kidney 293 cell line was seeded
at 5 x 104 cells per well in 6-well plates. Next day cells
were transduced with serial ten-fold dilutions of IN
competent LV-GFP-IRES-Neo, IN defective IDLV-GFP-
IRES-Neo and SIV-Vpx carrying IN defective IDLV-
GFP-IRES-Neo/Vpx vectors (range 1 x 105 to 1 x 101 RT
counts for the IN competent vector and 1 x 106 to 1 x 102
RT counts for IDLV). The medium was removed 24 hours
later and replaced with medium supplemented with
800 μg of Geneticin (Gibco Invitrogen) every 3 days. Cells
were grown for two weeks, and developed clones were
fixed with methanol and stained with Giemsa (Sigma).
Clones on each well were counted and expressed as num-
ber of colonies/106 RT counts. One separate well infected
with TY2-GFP-IRES-Neo/IN+was allowed to grow under
Geneticin pressure for production of 293/LV-GFP-Neo
cell line, used as a positive control for integration in the
vector sequence analysis.
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DNA from DC was extracted using the mi-Tissue Gen-
omic DNA Isolation Kit (Metabion International AG,
Martinsried, Germany). Extracted DNA was quantified
by determination of RNaseP content by Real-Time PCR
using 20X RNaseP Primer-Probe (Vic) Mix (Applied
Biosystems, Foster City, CA, USA). The integrated vec-
tor sequence was evaluated using a modified Alu-PCR
assay. The 293 cell line stably transduced with the TY2-
GFP-IRES-Neo vector (293/LV-GFP-Neo) was used as
standard for evaluating integrated vector copies and ab-
sence of circular forms. In a first set of amplifications,
two primers based on the human Alu repeat sequences,
forward primer (AluS: 50-TCCCAGCTACTGGGGAGG
CTGAGG-30), reverse primer (AluAs: 5’-GCCTCCCAA
AGTGCTGGGATTACAG-3’) and one forward primer
based on the CMV promoter sequence of the vector
(CMVfor: 50-ACGCCAATAGGGACTTTCCATTGAC-30)
(Eurofins MWG Operon, Ebersberg, Germany) were used
to generate a mixture of sequences. Reactions were per-
formed on 10, 2 and 0.1 ng of genomic DNA. Primers
were used at a final concentration of 300nM for AluS/AS
and 100 nM for CMV using 1X AmpliTaq Gold PCR
Master Mix (Applied Biosystems). PCR conditions were
95°C, 5 min; 94°C, 10 s; 60°C, 10 s; 72°C, 4 min, 25 cycles
of amplification. A nested PCR was performed on 1:100
dilution of the first PCR product using two internal pri-
mers in the vector genome (m902: 5'-AAAGGGACTG
GAAGGGCTAATTCACT-3'; AA55: 5'-CTGCTAGAGA
TTTTCCACACTGAC-3') producing a 230 bp amplicon
in the 3’LTR region. All primers were used at a final con-
centration of 300nM using 1X AmpliTaq Gold PCR Mas-
ter Mix (Applied Biosystems). PCR conditions were: 95°C,
5 min; 94°C, 30 s; 60°C, 30 s; 72°C, 30 s, with a final exten-
sion step of 10 min at 72°C for 35 cycles of amplication in
a 9700 Perkin-Elmer Thermocycler.
The quantification of 2-LTR (U3)–deleted circular
forms (2-dLTR) was performed by a quantitative real-
time PCR, using Syber Green I chemistry with 10, 5 and
2 ng of DNA and 900nM each of primers (477: 50-GTG
ACTCTGGTAACTAGAGA-30 and R485: 50-AGAGAG
CTCCCAGGCTCAG-30) spanning the junction between
the two U3-deleted (dU3) dLTR (U5–dU3). Amplifica-
tions were carried out in 25 μl of reaction volume, per-
formed in duplicate with 2X TaqMan Universal master
mix (Applied Biosystems). The kinetic PCR reaction
conditions were 1 cycle at 50°C, 2 min; 1 cycle at 95°C,
10 min; 40 cycles at 95°C, 15 s, 60°C, 1 min on the ABI
Prism 7500-FAST Real-Time PCR System (Applied Bio-
systems). The plasmid TA-2dLTR [9] was used to gener-
ate the standard curve (ranging from 10,000 to 1 copies)
for 2-dLTR DNA circles quantification, and each point
was performed in triplicate; fluorescent products were
detected at the last step of each cycle. After amplificationa melting curve was generated. HIV-1 and RNase P stand-
ard curves had slopes between −3.43 and −3.64 and the
coefficients of correlation were >0.99. All samples and
controls were run in duplicate and the normalized value of
2-dLTR copies was expressed as number of copies/100 ng
of total DNA.
The quantification of total vector DNA was performed
by a quantitative real-time PCR, using 10, 5 and 2 ng of
DNA in 15 μl final volume. Primers were used at a final
concentration of 500 nM while probe was 250 nM.
Sequences were as follow: mZ902: 5'-ACTGGAAGG
GCTAATTCACT-3'; ZAA55: 5'-GCTAGAGATTTTC
CACACTGAC-3' and probe 5’-(6-FAM)-CCAGAGTC
A-(ZEN)-CACAACAGACGGGCACA-3’(IABIkFQ) (IDT,
Leuven, Belgium). A standard curve, derived from serial
dilution of 293/LV-GFP-Neo cell line containing the target
sequence and ranging from 1 to 105 copies was measured
in triplicate. Reaction mixtures contained 1x TaqMan Fast
Universal PCR master mix (Applied Biosystems). After an
initial incubation at 95°C for 2 minutes, 40 cycles of amp-
lification were carried out as follows: denaturation for 3 s
at 95°C, annealing for 30 s at 60°C, and extension for 30 s
at 72°C. Reactions were carried out and analyzed using the
ABI Prism 7500-FAST Real-Time PCR System (Applied
Biosystems).
Mice immunization
Mice were kept in accordance with the European Union
guidelines and Italian legislation. All protocols were
approved by the authors' Institutional Review Board. Six
to eight weeks old BALB/c mice were injected once
intramuscularly with 7.2 × 106 RT units of either IDLV-
JR or IDLV-JR/Vpx vectors formulated in 0.2 ml of PBS.
Four mice were injected for each group and naïve ani-
mals were kept as negative control. Presence of HIV-
Env-specific CD8+ T cells was evaluated at different time
points after vaccination in blood. Mice were orbitally
bled collecting 200 μl of whole blood in the presence of
K-EDTA anticoagulant. Plasma were separated from cell
fractions by low speed centrifugation and kept at −80°C
for the measurement of anti-gp120 and anti-p24 anti-
bodies, as already described [9,25]. Leukocytes, obtained
after Ammonium Chloride Potassium (ACK) treatment,
were counted, suspended in complete medium contain-
ing 50μM 2- mercaptoethanol and analyzed for the pres-
ence of antigen specific T cells by IFNγ ELISPOT (BD
Biosciences), as already described [9] using H2-Dd-
restricted HIV-1 gp120 V3 loop epitope (IGPGRAFYT,
Primm) at 2 μg/ml. The unrelated GFP 9mer epitope
(HYLSTQSAL, Primm) and Concanavalin A (Sigma)
were used as negative and positive controls, respectively.
Samples were scored positive when a minimum of 50
spots per 106 cells and a fold of 2 or higher was present
compared to the unrelated peptide.
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Statistical analyses were performed by using Student’s t-
test. All P values were considered significant if less than
0.05.
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